Myeloid Malignancies Clinical Trial
Official title:
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Myeloid Malignancies
The goal of this clinical study is to learn more about the safety and dosing of the study drug, magrolimab (Mag), in combination with anti-leukemia therapies in participants with acute myeloid leukemia (AML).
The anti-leukemia therapies are defined as follows: - Venetoclax (Ven) - Azacitidine (Aza) - Mitoxantrone, etoposide, and cytarabine (MEC) This study consists of 3 safety run-in cohorts; - Safety Run-in Cohort 1 (1L Unfit AML Mag + Ven + Aza) - Safety Run-in Cohort 2 (R/R AML Mag + MEC) - Safety Run-in Cohort 3 (Post-chemo Maintenance Mag + CC-486) Participants will receive treatment at the assigned dose level for at least 4 cycles in the Safety Run-in cohorts, after which they may continue at the assigned dose level or switch to the RP2D upon agreement between the investigator and the sponsor. After completion of each safety run-in cohort and identification of the RP2D for that cohort, participants may be enrolled into the corresponding Phase 2 cohorts; - Phase 2 Cohort 1 (1L Unfit AML Mag + Ven + Aza) - Phase 2 Cohort 2 (R/R AML Mag + MEC) - Phase 2 Cohort 3 (Post-chemo Maintenance Mag + CC-486) Cycle length is 28 days for both the Safety Run-in and Phase 2 cohorts. Note: All cohorts are closed to screening and enrollment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06383572 -
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT01731951 -
Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
|
Phase 2 | |
| Recruiting |
NCT02958397 -
A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02958384 -
A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05775406 -
Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05807659 -
Fractionated Busulfan Conditioning Regimen for Allo-HSCT in Non-remission Myeloid Malignancies
|
Phase 2 | |
| Active, not recruiting |
NCT02452697 -
Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT
|
Phase 2 | |
| Terminated |
NCT01366612 -
PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation
|
Phase 3 | |
| Completed |
NCT03270748 -
Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies
|
Phase 2 | |
| Recruiting |
NCT05115630 -
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05796570 -
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
|
Phase 2 |